Morphine sulfate; naltrexone hydrochloride - Generic Drug Details

What are the generic sources for morphine sulfate; naltrexone hydrochloride and what is the scope of freedom to operate?

Morphine sulfate; naltrexone hydrochloride is the generic ingredient in one branded drug marketed by Alpharma Pharms and is included in one NDA. There are seven patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Morphine sulfate; naltrexone hydrochloride has seventy-four patent family members in twenty-three countries.

Summary for morphine sulfate; naltrexone hydrochloride

International Patents:	74
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	6
DailyMed Link:	morphine sulfate; naltrexone hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for morphine sulfate; naltrexone hydrochloride

Dosage:

CAPSULE, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for morphine sulfate; naltrexone hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 4
Pfizer	Phase 3
Ranbaxy Inc.	Phase 1

See all morphine sulfate; naltrexone hydrochloride clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for morphine sulfate; naltrexone hydrochloride

N02AA	Natural opium alkaloids
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

N07BB	Drugs used in alcohol dependence
N07B	DRUGS USED IN ADDICTIVE DISORDERS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

Paragraph IV (Patent) Challenges for MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	20 mg/0.8 mg	022321	1	2018-08-16
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	30 mg/1.2 mg 50 mg/2 mg 80 mg/3.2 mg	022321	1	2010-05-28
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	60 mg/2.4 mg	022321	1	2010-05-25
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	100 mg/4 mg	022321	1	2010-05-03

US Patents and Regulatory Information for morphine sulfate; naltrexone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-003	Aug 13, 2009		DISCN	Yes	No			Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-003	Aug 13, 2009		DISCN	Yes	No
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-006	Aug 13, 2009		DISCN	Yes	No			Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009		DISCN	Yes	No			Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-002	Aug 13, 2009		DISCN	Yes	No
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-006	Aug 13, 2009		DISCN	Yes	No
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009		DISCN	Yes	No			Y

Expired US Patents for morphine sulfate; naltrexone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-004	Aug 13, 2009
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-001	Aug 13, 2009
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-006	Aug 13, 2009
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-002	Aug 13, 2009

International Patents for morphine sulfate; naltrexone hydrochloride

Country	Patent Number	Title	Estimated Expiration
Mexico	2008016372	COMPOSICIONES FARMACEUTICAS. (PHARMACEUTICAL COMPOSITIONS.)
Portugal	1551372
Slovenia	2484346
Poland	2484346
Denmark	2484346
Japan	5566102
Hong Kong	1173980

Market Dynamics and Financial Trajectory for Morphine Sulfate and Naltrexone Hydrochloride

Last updated: February 19, 2026

What Are the Market Sizes and Growth Trends for Morphine Sulfate and Naltrexone Hydrochloride?

Morphine sulfate and naltrexone hydrochloride occupy distinct segments in the pharmaceutical industry, with their market sizes driven by different factors.

Metric	Morphine Sulfate	Naltrexone Hydrochloride
2022 Global Market Value	Approx. US$850 million	Approx. US$350 million
Compound Annual Growth Rate (CAGR, 2022-2028)	~2.5%	~4.2%
Key Market Drivers	Chronic pain management, hospital use, regulatory approvals	Opioid addiction treatment, alcohol dependence
Geographic Distribution	North America (~40%), Europe (~25%), Asia-Pacific (~30%)	North America (~50%), Europe (~20%), Asia-Pacific (~20%)

Market growth for morphine sulfate remains moderate, primarily driven by the high prevalence of chronic pain and cancer-related pain in aging populations. The opioid crisis has led to stricter regulations, slightly suppressing growth. Naltrexone hydrochloride, on the other hand, benefits from increasing awareness of addiction treatment options and expanded off-label uses.

How Do Regulatory Environments Affect Market Trajectories?

Morphine sulfate faces increasing restrictions amid opioid misuse concerns. Key regulatory challenges include:

• US FDA classifies it as a Schedule II controlled substance.
• European Medicines Agency (EMA) imposes licensing constraints.
• Stringent prescribing protocols reduce total prescriptions in developed markets.

Naltrexone hydrochloride faces fewer restrictions:

• Approved in multiple forms, including oral and injectable.
• Growing acceptance in medication-assisted treatment (MAT).
• Off-label uses expanding, including for alcohol dependence.

Patent Status and Generic Competition

Drug	Patent Expiry	Number of Generics (2022)	Price Trends (2022)	R&D Activity
Morphine sulfate	Not under patent; patents expired decades ago	Numerous generics available	Prices declined 10–15% YoY	Limited due to patent expiry
Naltrexone hydrochloride	Compound patent expired (e.g., Vivitrol in 2011)	Several generics	Prices stable but declining, ~8% YoY	Active R&D for new formulations and delivery methods

The patent landscape significantly influences revenues, with generic versions reducing pharmaceutical margins over time.

Market Players and Competitive Dynamics

Major companies involved:

• Morphine sulfate: Pfizer, Sandoz, Hikma Pharmaceuticals.
• Naltrexone hydrochloride: Alkermes, Mylan (now part of Viatris), Teva Pharmaceuticals.

Market share shifts occur as companies introduce novel formulations or biosimilars. For example, sustained-release naltrexone (Vivitrol) maintains high margins due to unique formulation patents, despite generic competition.

Financial Projections and Investment Considerations

Morphine sulfate expected revenues stagnate or decline slowly due to regulatory pressures and declining domestic US prescriptions. Growth potential exists in emerging markets with less regulation but is tempered by access challenges.

Naltrexone hydrochloride projects higher growth driven by:

• Increased approval for new indications.
• Development of long-acting injectable forms.
• Growth in addiction treatment markets, notably in Asia-Pacific.

Expected compound revenue growth over five years:

Drug	2023 Forecast	2028 Forecast
Morphine sulfate	~$820 million	~$900 million
Naltrexone hydrochloride	~$370 million	~$470 million

Investors should consider market saturation, generic pricing pressures, and regulatory risks. Both drugs face competitive pressures but differing growth prospects hinge on innovation and market expansion.

Key Market Challenges

• Regulatory compliance costs rising for opioids.
• Increasing generic competition compresses margins.
• Limited pipeline innovation for established medications.
• Supply chain vulnerabilities, especially for raw materials.

Key Opportunities

• Novel delivery systems (e.g., transdermal patches, long-acting injectables).
• Expanding into emerging markets with unmet needs.
• Repurposing existing formulations for new indications.
• Digital health integration for adherence monitoring.

Key Takeaways

• Morphine sulfate faces moderate, possibly declining, growth due to increased regulation; a mature market with slow innovation.
• Naltrexone hydrochloride shows higher near-term growth driven by addiction treatment demands; innovation in formulations fortifies market position.
• Patent expirations have fostered generic competition, placing downward pressure on prices.
• Regulatory landscape significantly influences market dynamics, especially for opioids.
• Growth opportunities lie in formulation innovations, emerging markets, and expanded indications.

FAQs

1. What factors most influence the growth of morphine sulfate?
Chronic pain prevalence, regulatory restrictions, and opioid misuse policies primarily shape its growth.

2. How does patent expiry affect naltrexone hydrochloride's market?
Patents expiring lead to generic entries, reducing prices but also allowing broader access and expanded market reach.

3. Are there new formulations in development for these drugs?
Yes; long-acting injectables and transdermal patches for naltrexone are in advanced stages. Morphine formulations focus on reducing abuse potential.

4. What markets offer the highest growth potential?
Emerging markets, especially in Asia-Pacific, present opportunities due to less restrictive regulations and rising healthcare infrastructure.

5. How will regulatory changes impact future revenues?
Tighter controls on opioids may suppress morphine sulfate sales, while relaxed regulations or approved new indications could boost naltrexone revenues.

---

References

[1] Statista. (2023). Global pharmaceutical market size. Retrieved from https://www.statista.com.

[2] BIS Research. (2022). Pain management drugs market analysis. Retrieved from https://bisresearch.com.

[3] U.S. Food and Drug Administration. (2022). Drug scheduling and regulations. Retrieved from https://www.fda.gov.

[4] European Medicines Agency. (2022). Prescription drug regulations. Retrieved from https://www.ema.europa.eu.

[5] IMS Health. (2022). Global drug price trends. Retrieved from https://imshealth.com.